Insider Selling: Natera (NASDAQ:NTRA) Insider Sells 1,639 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,639 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $230.77, for a total value of $378,232.03. Following the transaction, the insider directly owned 137,847 shares of the company’s stock, valued at $31,810,952.19. The trade was a 1.18% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, February 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $231.44, for a total transaction of $694,320.00.
• On Wednesday, January 28th, Solomon Moshkevich sold 1,200 shares of Natera stock. The stock was sold at an average price of $237.66, for a total transaction of $285,192.00.
• On Tuesday, January 27th, Solomon Moshkevich sold 1,013 shares of Natera stock. The shares were sold at an average price of $240.53, for a total transaction of $243,656.89.
• On Wednesday, January 21st, Solomon Moshkevich sold 293 shares of Natera stock. The stock was sold at an average price of $235.00, for a total transaction of $68,855.00.
• On Tuesday, January 20th, Solomon Moshkevich sold 23,205 shares of Natera stock. The stock was sold at an average price of $234.74, for a total transaction of $5,447,141.70.
• On Friday, January 2nd, Solomon Moshkevich sold 2,951 shares of Natera stock. The shares were sold at an average price of $228.95, for a total value of $675,631.45.
• On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The stock was sold at an average price of $230.76, for a total value of $1,082,725.92.
• On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $238.15, for a total value of $714,450.00.

Natera Stock Down 9.7%

Shares of NASDAQ NTRA traded down $22.07 during trading hours on Wednesday, reaching $205.61. 2,452,176 shares of the stock traded hands, compared to its average volume of 1,059,726. The company’s 50-day simple moving average is $234.95 and its two-hundred day simple moving average is $195.74. The company has a market capitalization of $28.44 billion, a P/E ratio of -89.79 and a beta of 1.64. Natera, Inc. has a 52-week low of $125.38 and a 52-week high of $256.36.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The business had revenue of $592.18 million for the quarter, compared to the consensus estimate of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The firm’s revenue was up 34.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.26) earnings per share. As a group, sell-side analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NTRA. Horizon Investments LLC bought a new position in shares of Natera in the 3rd quarter worth about $32,000. Hilltop National Bank purchased a new stake in shares of Natera during the second quarter valued at approximately $33,000. Sound Income Strategies LLC lifted its position in Natera by 95.7% in the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 110 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new stake in Natera during the 4th quarter valued at $41,000. Finally, Quent Capital LLC bought a new stake in shares of Natera in the 3rd quarter worth $46,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on NTRA. BNP Paribas Exane raised Natera to a “hold” rating and set a $172.00 price objective on the stock in a research note on Monday, October 27th. Barclays increased their target price on Natera from $230.00 to $270.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Morgan Stanley lifted their price target on Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a research note on Monday, December 1st. Canaccord Genuity Group reissued a “buy” rating on shares of Natera in a research note on Monday, January 12th. Finally, UBS Group raised their target price on shares of Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and an average price target of $249.20.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.